Skip to main content
Fig. 4 | Molecular Neurodegeneration

Fig. 4

From: A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice

Fig. 4

Effect of NB-360 on APP metabolites in APP51/16 mice, measured in Triton X100 extract 4 and 24 h after the last dose of a 6 week study (100 μmol/kg/d p.o.). a Aβ40, Aβ42, and sAPPβ in CSF, b Aβ40 in plasma, c Example of forebrain samples on Western blot stained with C-terminal APP antibody (green) and N-terminal Aβ antibody (red). B: baseline, 14.5 mo, V: vehicle 16 mo, T: treatment with NB-360, d quantification of Western blot data for C83 and C99. e MSD-immunoassay results for full-length APP, sAPPα, and sAPPβ in TX-100 forebrain extract. Data are means ± SEM, n = 8-17, all comparisons done against vehicle group

Back to article page